Business Wire

Mike Parrish Appointed as CEO, Howden U.S. and Jim Hays as Vice Chairman, Howden Group Holdings

4.8.2025 18:42:00 CEST | Business Wire | Press release

Share

Howden brings its unique entrepreneurial model, ambitious growth plans, and fresh choice for talent and clients to U.S. retail broking market

Howden, the global insurance intermediary group, today announces the appointment of Mike Parrish as Chief Executive Officer, Howden U.S., and of Jim Hays as Vice Chairman, Howden Group Holdings. Mike will build a next-generation U.S. retail broking business for clients and talent, bringing Howden’s unique employee-ownership driven and client-centric model to the largest and most dynamic insurance market in the world. Jim will bring more than 40 years’ U.S. insurance industry experience to the Howden Group Board.

Mike is one of the industry’s most successful business builders, with a proven track record of scaling highly successful U.S. operations. His appointment reflects Howden’s approach to empowering the very best leaders in each territory to build great businesses by attracting exceptional talent and giving that talent the freedom to put their clients at the heart of the business. Mike spent the best part of two decades at Aon, where he built a market-leading business, before joining Marsh in 2021. He will join Howden in September, subject to the fulfilment of relevant contractual obligations.

Jim is a deeply experienced U.S. insurance executive and entrepreneur who previously served as Chief Executive Officer of Hays Company, an insurance broker which he founded in 1994 and sold to Brown & Brown in 2018. He served as Vice Chair and as a member of the Board of Brown & Brown, Inc. He started Hays as a seven-person operation and oversaw more than 25 years of growth to build one of the leading independent U.S. brokers.

Howden started with three people in 1994 and has become a top 10 global broker with more than 22,000 people, including nearly 6,000 employee shareholders who own 34% of the Group. It has done this by attracting entrepreneurs to build businesses across 56 countries, today managing $47 billion in premiums and providing a full-service offering across retail, specialty, and reinsurance broking, risk capital advisory, employee benefits, and underwriting and program management.

Howden already has substantial operations in the U.S. where more than a quarter of its revenue is generated. It has operated in the U.S. for more than a decade through DUAL, one of the world’s largest Managing General Agents, through Howden Re, one of only four global reinsurance brokers, and through many years of supporting US-domiciled clients as their wholesale broker in international markets, with more than $18bn of US premiums today.

Jim Hays, Vice Chairman, Howden Group Holdings,said: “I could not be more energized to join this incredibly exciting, deeply ambitious Group with its army of entrepreneurs dedicated to serving clients. And of course, to work with David, who is in my view one of the most visionary leaders in business today. I was privileged to count Neil Armstrong as a personal friend, so the fact that the news of Howden’s further investment in the USA was first rumoured in the press on the 21st July - the day an American first walked on the Moon – was particularly apposite for me.”

David Howden, CEO, Howden,said: “From the beginning we built Howden on the principle that if we look after our people they will look after our clients. This means we hire great people and get out of their way, truly empowering them to do what’s best for their clients. This is why our organic growth consistently outperforms the market.

“Mike’s appointment is an incredibly important moment in our 30-year history of building a global group with an energetic and entrepreneurial culture, owned by the people who work in it. The foundation of our success has always been in finding the right leaders who are driven to build a business they can be proud of. In Mike we’ve found one of insurance’s most outstanding leaders, with an owner’s mindset and an unrivalled track-record, who wants the freedom to build a business that is an alternative home for talent and clients in the U.S. And in Jim we have one of the most accomplished entrepreneurs in the U.S., who brings a wealth of experience to the Group Board as we accelerate towards our ambitious 2030 vision.

“I am passionate about the role insurance can play in the world, facilitating growth and helping to solve some of the biggest challenges we are facing. In a consolidating market we’re answering a clear desire from clients, insurers, and talent for choice by being the destination for top talent. And I am especially proud that when others in the broking market are cutting costs, we are investing to create jobs in the U.S. to provide better service to clients. We will combine the full weight of our global capabilities to deliver expertise and service with a difference in the U.S. and internationally.

“Our doors are now open. We can’t wait to get started.”

About Howden

Howden is a global insurance intermediary group with employee ownership at its heart. Founded in 1994, it provides insurance broking, reinsurance broking and underwriting services and solutions to clients ranging from individuals to the largest multinational companies.

The group operates in 56 countries across Europe, Africa, Asia, the Middle East, Latin America, the USA, Australia and New Zealand, employing 22,000 people and handling $47bn of premium on behalf of clients.

Further information can be found at www.howdengroup.com and www.howdengroupholdings.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250804162079/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye